Which medications in the drug class Factor Xa Inhibitors are used in the treatment of Venous Thromboembolism (VTE)?

Updated: Nov 05, 2020
  • Author: Vera A De Palo, MD, MBA, FCCP; Chief Editor: Vinod K Panchbhavi, MD, FACS  more...
  • Print
Answer

Factor Xa Inhibitors

Blood coagulation cascade is dependent on the activation of factor X to factor Xa via the intrinsic and extrinsic pathways.

Apixaban (Eliquis)

Indicated to reduce risk of stroke and systemic embolism associated with nonvalvular atrial fibrillation. Also indicated for postoperative prophylaxis of DVT/PE and for treatment of DVT or PE.

Rivaroxaban (Xarelto)

Indicated for prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery. Also indicated to reduce the risk of stroke in patients with nonvalvular atrial fibrillation. Additionally, it is indicated for treatment of DVT or PE.

Edoxaban (Savaysa)

Indicated to reduce risk of stroke and systemic embolism associated with nonvalvular atrial fibrillation (NVAF).

Betrixaban (Bevyxxa)

Indicated for prophylaxis of venous thromboembolism (VTE) in adults hospitalized for acute medical illness who are at risk for thromboembolic complications owing to moderate or severe restricted mobility and other risk factors that may cause VTE.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!